Modulation of the alternative complement pathways by beta 1 H globulin
- PMID: 62817
- PMCID: PMC2190448
- DOI: 10.1084/jem.144.5.1147
Modulation of the alternative complement pathways by beta 1 H globulin
Abstract
C3b inactivator accelerator (A-C3bINA) was isolated from human plasma. An antiserum produced against the purified protein gave a reaction of identity with beta 1 H, a well-documented contaminant of C3 preparations. Beta 1 H appears to be composed of a single polypeptide chain containing a significant quantity of carbohydrate, and having a sedimentation coefficient of 5.6 on analytical, and 6.4 on sucrose density gradient ultracentrifugation. Its mol wt based on SDS polyacrylamide gel electrophoresis and equilibrium sedimentation is approximately 150,000, whereas it elutes from Sephadex G200 with an apparent mol wt of 300,000, suggesting that beta 1 H is an asymmetric molecule. Beta 1 H potentiates the inactivation of C3b by C3b inactivator, binds to EAC43 to limit the formation of EAC43bB and EAC43bBP, and in contrast to C3b inactivator, it increases the rate of loss of hemolytic sites from EAC43bB and EAC43bBP. For the C3b inactivator-potentiating effect, beta 1 H and C3b inactivator must necessarily be simultaneously present. The kinetics of inactivation of C3b by C3b inactivator and beta 1 H are first order, suggesting that potentiation is not a multistep process. The mechanisms of binding to C3b and inhibition of the alternative pathway convertases C3bB and C3bBP are currently unknown.
Similar articles
-
C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.J Clin Invest. 1976 Jun;57(6):1554-63. doi: 10.1172/JCI108426. J Clin Invest. 1976. PMID: 819459 Free PMC article.
-
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.J Exp Med. 1977 Jul 1;146(1):257-70. doi: 10.1084/jem.146.1.257. J Exp Med. 1977. PMID: 301546 Free PMC article.
-
A molecular concept of the properdin pathway.Proc Natl Acad Sci U S A. 1976 Feb;73(2):612-6. doi: 10.1073/pnas.73.2.612. Proc Natl Acad Sci U S A. 1976. PMID: 54923 Free PMC article.
-
Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.Transplant Proc. 1977 Mar;9(1):729-39. Transplant Proc. 1977. PMID: 325806 Review.
-
A molecular basis of activation of the alternative pathway of human complement.Adv Exp Med Biol. 1979;120B:3-17. Adv Exp Med Biol. 1979. PMID: 390986 Review.
Cited by
-
Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro.Immunology. 1978 Dec;35(6):971-80. Immunology. 1978. PMID: 104925 Free PMC article.
-
Inhibition of the alternative pathway of complement by glomerular chondroitin sulphate proteoglycan.Immunology. 1992 Jul;76(3):373-7. Immunology. 1992. PMID: 1382039 Free PMC article.
-
Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins.J Exp Med. 1978 Dec 1;148(6):1722-7. doi: 10.1084/jem.148.6.1722. J Exp Med. 1978. PMID: 722244 Free PMC article.
-
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.PLoS Pathog. 2010 Jul 29;6(7):e1001027. doi: 10.1371/journal.ppat.1001027. PLoS Pathog. 2010. PMID: 20686663 Free PMC article.
-
Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci.Infect Immun. 2005 Nov;73(11):7390-7. doi: 10.1128/IAI.73.11.7390-7397.2005. Infect Immun. 2005. PMID: 16239538 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous